

Jaishri O Blakeley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2897413/publications.pdf>

Version: 2024-02-01

133
papers

6,212
citations

81900

39
h-index

76900

74
g-index

139
all docs

139
docs citations

139
times ranked

6899
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426. | 1.6 | 67 |
| 2 | Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. <i>ELife</i> , 2022, 11, . | 6.0 | 4 |
| 3 | Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383. | 1.2 | 1 |
| 4 | Review and consensus recommendations on clinical ^{3T}-weighted imaging approaches at ^{3T}: Application to brain tumors. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 546-574. | 3.0 | 79 |
| 5 | Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988. | 1.2 | 14 |
| 6 | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1246-1258. | 4.1 | 2 |
| 7 | Management of neurofibromatosis type 1-associated plexiform neurofibromas. <i>Neuro-Oncology</i> , 2022, 24, 1827-1844. | 1.2 | 29 |
| 8 | Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2672-2683. | 1.2 | 4 |
| 9 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856. | 1.2 | 30 |
| 10 | Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. <i>NeuroImage: Clinical</i> , 2022, , 103121. | 2.7 | 4 |
| 11 | Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. <i>Acta Neuropathologica</i> , 2021, 141, 101-116. | 7.7 | 26 |
| 12 | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173. | 30.7 | 46 |
| 13 | Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425. | 1.6 | 9 |
| 14 | DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS. <i>Neuro-Oncology Advances</i> , 2021, 3, i13-i13. | 0.7 | 0 |
| 15 | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806. | 1.6 | 54 |
| 16 | Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513. | 2.4 | 290 |
| 17 | Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1584-1591. | 4.1 | 11 |
| 18 | Validating Techniques for Measurement of Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S32-S41. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. <i>Neurology</i> , 2021, 97, e953-e963. | 1.1 | 18 |
| 20 | Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S15-S24. | 1.1 | 5 |
| 21 | Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. <i>Neurology</i> , 2021, 97, S99-S110. | 1.1 | 2 |
| 22 | Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S111-S119. | 1.1 | 6 |
| 23 | Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. <i>Neurology</i> , 2021, 97, S42-S49. | 1.1 | 2 |
| 24 | Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. <i>PLoS ONE</i> , 2021, 16, e0252048. | 2.5 | 19 |
| 25 | Approach to patients with the neoplasms associated with neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. , 2021, , 210-228. | | 0 |
| 26 | Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154. | 0.7 | 13 |
| 27 | Brain Cancers in Genetic Syndromes. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 64. | 4.2 | 4 |
| 28 | An update on the central nervous system manifestations of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2020, 139, 625-641. | 7.7 | 64 |
| 29 | Moyamoya disease versus moyamoya syndrome: comparison of presentation and outcome in 338 hemispheres. <i>Journal of Neurosurgery</i> , 2020, 133, 1441-1449. | 1.6 | 16 |
| 30 | The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 397-408. | 4.1 | 18 |
| 31 | Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. <i>Skeletal Radiology</i> , 2020, 49, 199-219. | 2.0 | 69 |
| 32 | <scp>d</scp>â€glucose weighted chemical exchange saturation transfer (glucoCEST)â€based dynamic glucose enhanced (DGE) MRI at 3T: early experience in healthy volunteers and brain tumor patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 247-262. | 3.0 | 41 |
| 33 | Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, i117-i123. | 0.7 | 3 |
| 34 | The development of the PlexiQoL: A patientâ€reported outcome measure for adults with neurofibromatosis type 1â€associated plexiform neurofibromas. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1530. | 1.2 | 3 |
| 35 | Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28372. | 1.5 | 3 |
| 36 | Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442. | 27.0 | 360 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. <i>Neuro-Oncology</i> , 2020, 22, 1368-1378. | 1.2 | 37 |
| 38 | A clinically and genomically annotated nerve sheath tumor biospecimen repository. <i>Scientific Data</i> , 2020, 7, 184. | 5.3 | 19 |
| 39 | Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1. <i>Genes</i> , 2020, 11, 226. | 2.4 | 11 |
| 40 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784. | 1.2 | 44 |
| 41 | Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 912-917. | 1.2 | 59 |
| 42 | NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOG AND THE NF CLINICAL TRIALS CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii420-iii421. | 1.2 | 9 |
| 43 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79. | 7.0 | 12 |
| 44 | Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36. | 1.2 | 114 |
| 45 | Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454. | 1.6 | 73 |
| 46 | The Diagnosis and Management of Neurofibromatosis Type 1. <i>Medical Clinics of North America</i> , 2019, 103, 1035-1054. | 2.5 | 116 |
| 47 | Telomere alterations in neurofibromatosis type 1-associated solid tumors. <i>Acta Neuropathologica Communications</i> , 2019, 7, 139. | 5.2 | 12 |
| 48 | RARE-15. OUTCOMES OF TREATMENT OF GLIOMAS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE I TREATED WITH RADIATION THERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi224-vi224. | 1.2 | 0 |
| 49 | ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi23-vi23. | 1.2 | 0 |
| 50 | DDIS-21. IN VITRO MICRODIALYSIS RECOVERY OF TRAMETINIB. <i>Neuro-Oncology</i> , 2019, 21, vi67-vi67. | 1.2 | 0 |
| 51 | ACTR-09. A PHASE 0 PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF EVEROLIMUS IN VESTIBULAR SCHWANNOMA (VS) AND MENINGIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi14-vi14. | 1.2 | 0 |
| 52 | QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204. | 1.2 | 0 |
| 53 | RARE-54. MEK INHIBITION FOR AGGRESSIVE GLIOMAS IN ADULTS WITH NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2019, 21, vi233-vi233. | 1.2 | 2 |
| 54 | QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICE-BASED TECHNOLOGY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi202. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Association between patient-reported outcomes and objective disease indices in people with NF2. <i>Neurology: Clinical Practice</i> , 2019, 9, 322-329. | 1.6 | 7 |
| 56 | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of <i>Nf1</i> -Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2321-2330. | 4.1 | 10 |
| 57 | Engaging a community to enable disease-centric data sharing with the NF Data Portal. <i>Scientific Data</i> , 2019, 6, 319. | 5.3 | 8 |
| 58 | Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet. <i>American Journal of Neuroradiology</i> , 2019, 40, 1908-1915. | 2.4 | 6 |
| 59 | Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561. | 7.0 | 104 |
| 60 | Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the <i>NF2</i> gene. <i>Laryngoscope</i> , 2019, 129, 967-973. | 2.0 | 15 |
| 61 | Effect of ketogenic diets on leukocyte counts in patients with epilepsy. <i>Nutritional Neuroscience</i> , 2019, 22, 522-527. | 3.1 | 12 |
| 62 | Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180. | 10.7 | 32 |
| 63 | Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. <i>Otology and Neurotology</i> , 2018, 39, 632-638. | 1.3 | 15 |
| 64 | Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. <i>American Journal of Human Genetics</i> , 2018, 102, 69-87. | 6.2 | 144 |
| 65 | Voice and Swallowing Dysfunction in Neurofibromatosis 2. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 505-510. | 1.9 | 9 |
| 66 | Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 19-27. | 2.8 | 22 |
| 67 | NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143. | 1.2 | 14 |
| 68 | NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i144-i144. | 1.2 | 0 |
| 69 | Radiation-Induced Myelitis: Initial and Follow-Up MRI and Clinical Features in Patients at a Single Tertiary Care Institution during 20 Years. <i>American Journal of Neuroradiology</i> , 2018, 39, 1576-1581. | 2.4 | 27 |
| 70 | Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018, 20, 897-906. | 1.2 | 41 |
| 71 | The biology of cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S14-S20. | 1.1 | 27 |
| 72 | Creating a comprehensive research strategy for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S1-S4. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350. | 2.5 | 17 |
| 74 | Cutaneous neurofibromas. Neurology, 2018, 91, S5-S13. | 1.1 | 79 |
| 75 | Clinical trial design for cutaneous neurofibromas. Neurology, 2018, 91, S31-S37. | 1.1 | 11 |
| 76 | Considerations for development of therapies for cutaneous neurofibroma. Neurology, 2018, 91, S21-S30. | 1.1 | 23 |
| 77 | EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology, 2018, 20, 1185-1196. | 1.2 | 22 |
| 78 | Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. Cancer Prevention Research, 2018, 11, 655-664. | 1.5 | 4 |
| 79 | Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Scientific Data, 2018, 5, 180106. | 5.3 | 20 |
| 80 | Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis. World Neurosurgery, 2017, 99, 19-25. | 1.3 | 4 |
| 81 | The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. Journal of Neuro-Oncology, 2017, 135, 47-56. | 2.9 | 10 |
| 82 | Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. European Journal of Cancer, 2017, 83, 9-18. | 2.8 | 82 |
| 83 | Low-grade Schwann cell neoplasms with leptomeningeal dissemination: clinicopathologic and autopsy findings. Human Pathology, 2017, 60, 121-128. | 2.0 | 6 |
| 84 | Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. Journal of Magnetic Resonance Imaging, 2016, 44, 794-803. | 3.4 | 22 |
| 85 | Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology, 2016, 18, ii13-ii20. | 1.2 | 27 |
| 86 | Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8. | 1.1 | 23 |
| 87 | Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology, 2016, 87, S13-20. | 1.1 | 15 |
| 88 | Current whole-body MRI applications in the neurofibromatoses. Neurology, 2016, 87, S31-9. | 1.1 | 65 |
| 89 | Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro-Oncology, 2016, 18, ii26-ii36. | 1.2 | 22 |
| 90 | Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. Journal of Magnetic Resonance Imaging, 2016, 44, 456-462. | 3.4 | 132 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. American Journal of Medical Genetics, Part A, 2016, 170, 1455-1461. | 1.2 | 16 |
| 92 | Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-associated Vestibular Schwannomas. Journal of Clinical Oncology, 2016, 34, 1669-1675. | 1.6 | 92 |
| 93 | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology, 2016, 18, 624-638. | 1.2 | 94 |
| 94 | Cutaneous manifestations in neuro-oncology: clinically relevant tumor and treatment associated dermatologic findings. Seminars in Oncology, 2016, 43, 401-407. | 2.2 | 8 |
| 95 | Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients. PLoS ONE, 2015, 10, e0144620. | 2.5 | 10 |
| 96 | Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neuro-Oncology Practice, 2015, 2, 127-136. | 1.6 | 41 |
| 97 | Clinical Management of Seizures in Patients With Low-Grade Glioma. Seminars in Radiation Oncology, 2015, 25, 219-224. | 2.2 | 21 |
| 98 | How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?. JAMA Neurology, 2015, 72, 381. | 9.0 | 4 |
| 99 | ¹⁸ F-FDG PET/CT Qualitative and Quantitative Evaluation in Neurofibromatosis Type 1 Patients for Detection of Malignant Transformation: Comparison of Early to Delayed Imaging With and Without Liver Activity Normalization. Journal of Nuclear Medicine, 2015, 56, 379-385. | 5.0 | 54 |
| 100 | First-in-Human Dose Study of the Novel Transforming Growth Factor- β 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research, 2015, 21, 553-560. | 7.0 | 199 |
| 101 | Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Journal of Neuro-Oncology, 2015, 125, 123-131. | 2.9 | 8 |
| 102 | Clinical response to bevacizumab in schwannomatosis. Neurology, 2014, 83, 1986-1987. | 1.1 | 33 |
| 103 | High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology, 2014, 83, 235-239. | 1.1 | 120 |
| 104 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. Journal of Neuro-Oncology, 2014, 116, 59-65. | 2.9 | 24 |
| 105 | Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nature Genetics, 2014, 46, 182-187. | 21.4 | 242 |
| 106 | Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging. Skeletal Radiology, 2013, 42, 1317-1322. | 2.0 | 23 |
| 107 | Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opinion on Investigational Drugs, 2013, 22, 443-462. | 4.1 | 77 |
| 108 | Histopathological correlates with survival in reoperated glioblastomas. Journal of Neuro-Oncology, 2013, 113, 485-493. | 2.9 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 93-100. | 2.3 | 15 |
| 110 | Achieving consensus for clinical trials. <i>Neurology</i> , 2013, 81, S1-5. | 1.1 | 59 |
| 111 | Clinical Reasoning: Multiple cranial neuropathies in a young man. <i>Neurology</i> , 2013, 80, e60-6. | 1.1 | 4 |
| 112 | Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1119-1128. | 3.4 | 181 |
| 113 | Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. <i>ISRN Radiology</i> , 2013, 2013, 1-9. | 1.2 | 24 |
| 114 | Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 372-379. | 1.8 | 21 |
| 115 | Chemotherapy with cytotoxic and cytostatic agents in brain cancer. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 229-254. | 1.8 | 9 |
| 116 | Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer-Associated Leptomeningeal Disease. <i>Clinical Breast Cancer</i> , 2012, 12, 445-449. | 2.4 | 6 |
| 117 | The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 129-139. | 2.3 | 14 |
| 118 | Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 24-41. | 1.2 | 101 |
| 119 | Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. <i>Nature Medicine</i> , 2011, 17, 130-134. | 30.7 | 448 |
| 120 | Tissue concentration of systemically administered antineoplastic agents in human brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 104, 629-638. | 2.9 | 122 |
| 121 | Pineal Region Tumors. , 2011, , 435-455. | | 2 |
| 122 | Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1477-1491. | 3.3 | 36 |
| 123 | Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. <i>Clinical Cancer Research</i> , 2009, 15, 5032-5039. | 7.0 | 74 |
| 124 | Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. <i>Journal of Neuro-Oncology</i> , 2009, 91, 51-58. | 2.9 | 112 |
| 125 | Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. <i>Journal of Neuro-Oncology</i> , 2009, 93, 61-77. | 2.9 | 48 |
| 126 | Neoplastic and Paraneoplastic Disorders. , 2009, , 233-247. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Drug delivery to brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 235-241. | 4.2 | 75 |
| 128 | Anaplastic oligodendroglioma. <i>Current Treatment Options in Neurology</i> , 2008, 10, 295-307. | 1.8 | 19 |
| 129 | Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. <i>Magnetic Resonance in Medicine</i> , 2008, 60, 842-849. | 3.0 | 304 |
| 130 | Thrombolytic therapy for acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2007, 261, 55-62. | 0.6 | 57 |
| 131 | Quantitative description of the asymmetry in magnetization transfer effects around the water resonance in the human brain. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 786-793. | 3.0 | 196 |
| 132 | Management of pineal region tumors. <i>Current Treatment Options in Oncology</i> , 2006, 7, 505-516. | 3.0 | 85 |
| 133 | Case 5: altered mental status and fever after resection of glioblastoma multiforme. <i>MedGenMed: Medscape General Medicine</i> , 2004, 6, 49. | 0.2 | 2 |